HCA Healthcare, Inc. 8-K

What Happened

• HCA Healthcare filed an 8-K (Item 5.02) on June 18, 2026 reporting that, by agreement dated June 15, 2026, Dr. Michael Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026.
• Dr. Cuffe will continue with the company in a transitional role through February 2027. The filing states he will be eligible to receive benefits under HCA’s executive severance policy and applicable incentive plans.

Key Details

• Executive: Dr. Michael Cuffe, Executive Vice President & Chief Clinical Officer.
• Step-down effective date: August 31, 2026.
• Transitional period: through February 2027.
• Compensation/benefits: eligible for benefits per the company’s executive severance policy and applicable incentive plans (no dollar amounts disclosed).

Why It Matters

• This is a change in senior clinical leadership disclosed under Item 5.02; investors should note the timing of the departure and the planned transition period for continuity.
• The filing confirms potential severance/incentive payments under existing policies, but it does not disclose specific financial terms or a successor. Investors may want to watch for updates on replacement plans or any material compensation disclosures.